Pleiogenix is a unique, turn-key bio-pharmaceutical company that is focused on developing safe and effective treatments for liver and other fibrotic diseases with significant unmet medical needs.

Bentham Science is a science, technology, and medical publisher, providing academic researchers and industrial professionals with the latest information in diverse fields of science and technology. Our peer-reviewed scholarly journals and books have an ever-increasing readership of millions of researchers worldwide.

NNB is a global company of motivated thinkers, creators, developers, and innovators. They employ over 100 scientists from more than 10 countries who study, design, and deliver unique ingredients to our industry: to maximize health, augment performance, expand longevity, and enhance appearance. NNB fosters close partnerships with customers in the fields of nutraceuticals, pharmaceuticals and medical research. #ergothioneine

Healthy-Finds is all about extending a helping hand to up-and-coming health and wellness brands that they have decided are too good not to share.

bruxAway....improving human health, one person at a time...

P & N Development Ventures is a provider of a variety of product / business development / consulting services to food, nutritional, medical writing, pharmaceutical, and venture capital organizations (start-ups, private, and publicly traded).

Novus International, through its human nutrition business unit (Stratum Nutrition) is a business-to business supplier of branded human ingredients for the dietary supplement and food industries. Primary individual responsible for scientific and clinical activities supporting nutritional ingredient portfolio

Xymogen is a practitioner-, patient,- and employee-focused company that provides science-based dietary supplements and functional foods to licensed, healthcare professionals. Xymogen is one of the leading companies in this market space.

ReceptorBio was a biopharmaceutical start-up focused on identifying and commercializing Rx agents for type 2 diabetes and cardiovascular disease. It was co-founded by Professors David Klonoff, Ira Goldfine, and Joseph L. Evans.

Leptogen was a biopharmaceutical start-up focused on identifying and commercializing Rx agents that increased leptin and/or adiponectin for type 2 diabetes and cardiovascular disease.

MRI was a privately-held, science-based nutraceutical company founded in 1997 by Mr. Edward Byrd (co-founder of EAS, Inc, along with Anthony Almada, MSc, FISSN) that focused on the identification and commercialization of natural compounds that improved exercise performance, glucose metabolism, cardiovascular function, or reduced oxidative stress using proprietary controlled release delivery technology. MRI was also a leader in introducing clinically evaluated new products for the sports nutrition market. MRI was acquired by Natrol (Chatsworth, CA) in 2007.Dr. Evans was the primary individual responsible for providing scientific leadership and expertise in product development, manufacturing, regulatory affairs, technology evaluation, and clinical research (currently marketed products: ALAmax CR™ (Controlled release alpha-lipoic acid; Xymogen), NOmax ER™ (controlled release arginine alpha-ketoglutarate; Xymogen), CE2™ (creatine ethyl ester).

Telik was a biopharmaceutical company focused on identifying and commercializing Rx agents for cancer, type 2 diabetes, and immunological diseases.

Sugen was founded in 1991 in Redwood City, California, by biotech investor Stephen Evans-Freke, along with Drs Joseph Schlessinger, Axel Ullrich, and Peter Hirth.

Shaman Pharmaceuticals was a South San Francisco biotechnology company founded in 1990 by Lisa Conte, MBA (the first ever female CEO of a biotechnology company) that identified and isolated individual natural compounds from plants as sources of new drugs.

Sandoz is a global leader in generic pharmaceuticals and biosimilars. Their purpose is to discover new ways to improve and extend people’s lives. In the early 1990s, they possessed a serious interest in discovering and developing new drugs for type 2 diabetes.